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Abstract
Background: Poisoning with organophosphorus (OP) insecticides is a major global public health problem, causing an
estimated 200,000 deaths each year. Although the World Health Organization recommends use of pralidoxime, this
antidote’s effectiveness remains unclear. We aimed to determine whether the addition of pralidoxime chloride to atropine
and supportive care offers benefit.
Methods and Findings: We performed a double-blind randomised placebo-controlled trial of pralidoxime chloride (2 g
loading dose over 20 min, followed by a constant infusion of 0.5 g/h for up to 7 d) versus saline in patients with
organophosphorus insecticide self-poisoning. Mortality was the primary outcome; secondary outcomes included intubation,
duration of intubation, and time to death. We measured baseline markers of exposure and pharmacodynamic markers of
response to aid interpretation of clinical outcomes. Two hundred thirty-five patients were randomised to receive
pralidoxime (121) or saline placebo (114). Pralidoxime produced substantial and moderate red cell acetylcholinesterase
reactivation in patients poisoned by diethyl and dimethyl compounds, respectively. Mortality was nonsignificantly higher in
patients receiving pralidoxime: 30/121 (24.8%) receiving pralidoxime died, compared with 18/114 (15.8%) receiving placebo
(adjusted hazard ratio [HR] 1.69, 95% confidence interval [CI] 0.88–3.26, p= 0.12). Incorporating the baseline amount of
acetylcholinesterase already aged and plasma OP concentration into the analysis increased the HR for patients receiving
pralidoxime compared to placebo, further decreasing the likelihood that pralidoxime is beneficial. The need for intubation
was similar in both groups (pralidoxime 26/121 [21.5%], placebo 24/114 [21.1%], adjusted HR 1.27 [95% CI 0.71–2.29]). To
reduce confounding due to ingestion of different insecticides, we further analysed patients with confirmed chlorpyrifos or
dimethoate poisoning alone, finding no evidence of benefit.
Conclusions: Despite clear reactivation of red cell acetylcholinesterase in diethyl organophosphorus pesticide poisoned
patients, we found no evidence that this regimen improves survival or reduces need for intubation in patients with
organophosphorus insecticide poisoning. The reason for this failure to benefit patients was not apparent. Further studies of
different dose regimens or different oximes are required.
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Introduction
Organophosphorus (OP) insecticide poisoning is a major global
clinical problem, killing an estimated 200,000 people each year
[1,2]. Restricting agricultural use of highly toxic OP insecticides
will reduce regional suicide rates [3,4]. However, current
agricultural policies [5] make it unlikely that they will soon be
banned. Effective clinical therapies are required [6].
OP compounds inhibit acetylcholinesterase (EC 3.1.1.7),
resulting in overstimulation of cholinergic synapses [7,8]. Patients
die mostly from respiratory failure and lung injury [8,9], although
there is variability in the clinical syndrome [10–12]. Treatment
involves resuscitation, administration of the muscarinic antagonist
atropine [13], and an oxime acetylcholinesterase reactivator [14],
such as pralidoxime, and assisted ventilation as necessary [15].
The beneficial effects of atropine are clear [13,16]. By contrast, the
role of oximes is still the subject of much debate [17–19].
Clinical experience in Asia with regimens of 1 g pralidoxime
every 4–6 h for 1–3 d has lead to widespread doubt about its
efficacy in treatment of OP insecticide poisoning [20,21]. Two
meta-analyses concluded that pralidoxime causes harm [18,22]
but both included nonrandomised historical studies as well as
randomised controlled trials (RCTs). Proponents of oximes,
including the World Health Organization (WHO), believe that
the doses used were too low to be effective and recommended a
higher dosing regimen (at least 30 mg/kg pralidoxime salt loading
dose followed by 8 mg/kg infusion) [23,24]. Furthermore, the
studies did not account for variable acetylcholinesterase ageing (a
nonenzymatic alteration of phosphorylated acetylcholinesterase
that prevents reactivation by oximes) caused by different classes of
insecticide [14].
We set up an RCT in two Sri Lankan district hospitals in 2004
to compare the WHO-recommended regimen of pralidoxime with
placebo in OP insecticide poisoning.
Methods
The RCT was conducted in Anuradhapura and Polonnaruwa
district hospitals, Sri Lanka. Ethics approval was received from the
Faculty of Medicine Ethics Committee, Colombo, and Oxford-
shire Clinical Research Ethics Committee. Written informed
consent was taken from each patient, or their relative (for patients
unconscious or under the age of 16 y), in their own language.
Participants
We approached all patients with OP insecticide self-poisoning
admitted to adult wards who required atropine according to our
protocol [15]. The exclusion criteria were: age ,14 y, known
pregnancy, receipt of pralidoxime at a transferring hospital, and
previous recruitment to this RCT. The OP insecticide was
identified from the history or clinical syndrome (sources previously
found to be highly accurate [11]). Patients were seen by study
doctors within 30 min of admission and treated as described [15].
Outcome, Objectives, and Hypotheses
The primary aim was to determine whether pralidoxime
chloride reduced all-cause mortality during hospital admission
after OP self-poisoning compared with no pralidoxime. Secondary
outcomes included intubation, time to intubation, time ventilated,
and time to death.
We performed prespecified subgroup analyses to determine
whether any effect was consistent between patients poisoned with
dimethyl versus diethyl organophosphorus insecticides, patients
poisoned by the two most common pesticides (dimethoate,
chlorpyrifos [11]), and whether any effect was dependent on time
from ingestion to treatment or Glasgow coma scale (GCS) score on
admission. We adjusted these analyses according to baseline red
cell acetylcholinesterase (EC 3.1.1.7) ageing and plasma insecticide
concentration measured retrospectively.
A post-hoc analysis was performed to assess whether any effect
noted was consistent for patients intubated or not intubated at
baseline.
Randomisation
Patients were randomised into one of two study arms to receive
saline placebo or pralidoxime chloride (2 g loading dose over
20 min, then a constant infusion of 0.5 g/h until a maximum of
7 d, atropine had not been required for 12–24 h, or death). The
random allocation sequence was generated by computer and
incorporated into a programme written for recruitment, rando-
misation, and event recording. Stratified block randomisation was
performed using: (i) chemical structure (diethyl, dimethyl,
unknown/other); (ii) reported time between poisoning and
recruitment (,4 h; 4–12 h; .12 h; unknown); (iii) status on
admission (GCS 14–15/15, GCS ,14), and (iv) allocation in a
concurrent RCT of activated charcoal [25].
The allocation sequences were generated independently by the
statistician and implemented by the programmer, neither of whom
interacted with patients. Variable block sizes were used to allocate
patients in equal numbers to each treatment group using Stata v. 7
software (ralloc subroutine version 3.2.5).
Participants were recruited and randomised by a study doctor at
the bedside using a dedicated handheld computer at each study
hospital. Randomisation occurred after baseline data had been
entered, and could not be altered by study doctors. The recruiting
doctor could not predict allocation accurately before randomisa-
tion.
Study Drug
Pralidoxime chloride was supplied by Pharmalab (New South
Wales, Australia) as a 6.25 g/250 ml preparation. The quality of
each batch was checked independently (SGS Lanka Laboratories)
by HPLC on arrival in Sri Lanka (pralidoxime detected and
present at 92.5% to 110% of the expected quantity and pH 3.5 to
4.5 [USP standards]). All batches used for the study fulfilled USP
standards.
The study was double-blind. The pralidoxime and placebo were
provided in batches of vials, identical except for a serial number
starting with one of two letters: A or B, C or D, etc. At
randomisation, the computer program specified a letter; vials with
that letter were used for that patient. At intervals, the letter pairs
were shifted to the next pair to reduce the risk of unblinding.
Blood samples were subsequently assayed for pralidoxime; this
showed that all patients received the correct allocation.
Blood Sampling and Analysis of Pharmacokinetics and
Pharmacodynamics
Blood samples were taken from patients on recruitment and at
intervals thereafter for assay of plasma butyrylcholinesterase and
red cell acetylcholinesterase activity [26], pralidoxime, and
insecticide concentration. Sampling and assays were carried out
as described [11,27]. A technical problem caused the analysis of
samples from 30% of patients to be delayed, allowing ageing of
inhibited acetylcholinesterase to continue during storage (resulting
in a 200 mU/mmol Hb reduced maximal reactivation of diethyl-
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inhibited acetylcholinesterase but little apparent difference for
dimethyl-inhibited enzyme). These samples were included in the
results and reduced the overall median acetylcholinesterase
reactivation ex-vivo.
Sample Size
We calculated that to detect whether pralidoxime reduced the
case fatality in symptomatic patients from 25% to 19% (two-sided
significance level of 5%, power 80%), a minimum of 750 patients
was required in each arm. The trial was set up as a superiority
trial.
Independent Data Monitoring Committee
An independent data monitoring committee (IDMC) was
established for this and the concurrent trial [25]. Interim analyses
were to be supplied by the trial statistician to the IDMC Chair as
often as requested. In the light of interim data, and emerging
evidence from other studies, the IDMC then informed the
principal investigator if in their view there was proof beyond
reasonable doubt that the data indicated that any part of the
protocol under investigation became clearly indicated or contra-
indicated, or it was evident that no clear outcome would be
obtained. The trial stopped after the first interim analysis due to
lack of recruitment.
Statistical Analysis
Demographic factors and clinical characteristics were summa-
rised with counts (percentages) for categorical variables and
median (interquartile range [IQR]) for continuous variables, as
none were expected to be normally distributed. The main analysis
was carried out on an intention-to-treat basis. For the primary
outcome, death, and for secondary outcome postrandomisation
intubations, we reported the number and proportion of patients
experiencing an event.
For outcomes where time-to-event was recorded, we used the
logrank test to compare the treatment groups, producing Kaplan-
Meier curves to illustrate the comparison. In addition, we
calculated incidence rates and performed Cox’s regression to
estimate hazard ratios (HRs) (plus 95% confidence interval [CI]
and p-values) to establish the magnitude and direction of the
treatment effect, adjusted for stratification factors, hospital, and
intubation at baseline.
It was unclear how GCS on admission and time since ingestion
should be fitted in statistical models, so various models were fitted
using different approaches. The optimal statistical model was
chosen based on the lowest value for Akaike’s information
criterion (AIC) [28], a measure of the goodness of fit of a
statistical model, as long as the model was stable (AIC penalizes
more complex models).
The statistical test of interaction was used to examine whether
the treatment effects were consistent across poison subgroups
(dimethyl, diethyl, unknown) and in those intubated/not intubated
at baseline. A term representing the interaction was entered into
the baseline statistical model and a Wald test performed to test for
the presence of an interaction. Of note, however, the study size
meant that we had limited power for analyzing interactions. An
exploratory analysis using Cox’s regression investigated the effects
of potentially important prognostic factors such as percentage of
aged acetylcholinesterase on admission and OP concentration on
admission.
The Chi-squared test was used to compare the proportions of
patients dying in red cell acetylcholinesterase activity groups.
Median red cell acetylcholinesterase activity in survivors and
fatalities, and median length of time intubated in each group, were
compared using the Mann-Whitney U test.
Results
Patients were enrolled from 26 May 2004 until 18 October
2006. Unfortunately, discussion of the results of an RCT [29]
performed in Baramati, India, that suggested marked benefit from
pralidoxime at a seminar in August 2005, resulted in loss of
equipoise (the perception of treatments being of equal value) by
clinicians, a fall off in recruitment, and early termination of the
trial.
Participants
A total of 1,150 patients with OP poisoning were assessed on
admission; 653 were asymptomatic, 162 excluded for other
reasons, and 100 refused consent (Figure 1). 235 symptomatic
patients were eligible, consented, and randomised into the trial:
114 received saline placebo and 121 received pralidoxime
chloride.
Baseline demographic and clinical characteristics are presented
in Tables 1 and 2. Although broadly similar, there were differences
due to the relatively small number of patients recruited. In
particular, more severely poisoned patients were allocated to
pralidoxime, as shown by the proportion who were intubated
before randomisation and had a GCS ,14/15 (Table 1). Median
time to recruitment was 4.3 h (IQR 2.9–7.6 h) postingestion.
Assessment of Adequacy of the Pralidoxime Regimen
We first assessed the regimen’s pharmacokinetics/dynamics to
ensure that it had been adequate. It produced a steady state
plasma pralidoxime concentration of approximately 100 mmol/l
(Figure 2). We found no consistent difference in steady state
concentration between patients who died and survivors (unpub-
lished data).
Pralidoxime effectively reactivated red cell acetylcholinesterase
inhibited by diethyl OP insecticides but only moderately
reactivated dimethyl OP-inhibited enzyme (Figure 3). Diethyl
OP insecticides in this study included chlorpyrifos, quinalphos,
and diazinon; dimethyl OP insecticides included dimethoate,
fenthion, phenthoate, and oxydemeton-methyl. All are WHO
Class II toxicity pesticides [30]. There was no reactivation for
either class after placebo.
Primary Outcome—Mortality
Overall mortality in the trial was 48/235 (20.4%). Case fatality
was higher in patients receiving pralidoxime compared to placebo
(30/121 [24.8%] versus 18/114 [15.8%]; crude estimated HR:
1.82 [95% CI 1.01–3.28, p=0.05]). Adjustment for stratification
variables, and for intubation at baseline, resulted in a revised
estimated HR of 1.69 (95% CI 0.88–3.26, p=0.12), suggesting no
difference between groups.
Patients died sooner after pralidoxime compared to placebo
(Figure 4); however, this is partly explained by the baseline
imbalance in GCS score (GCS,14/15: pralidoxime 48/121
[39.7%] versus control 35/114 [30.7%]; GCS,7/15: pralidoxime
26/121 [21.5%] versus control 15/114 [13.2%]; low GCS being a
marker of poor prognosis [31]). Most of the difference in mortality
occurred between 12 h and 5 d postrandomisation (Figure 5).
Prespecified Subgroup Analysis
No differential effect was found for any of the prespecified
subgroups; in particular there was no improvement in mortality
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for diethyl compounds (HR 2.84, 95% CI 0.70–11.47; Figure 6),
despite good acetylcholinesterase reactivation.
We measured the plasma concentration of insecticide on
admission, as well as the percentage of acetylcholinesterase that
was aged at baseline, since both should affect the efficacy of
pralidoxime [14]. All the information was present for 164 of 235
(69.8%) patients; the groups were similar at baseline except for
small differences in OP class ingested and proportion intubated.
The adjusted HR for death for this smaller group of 164 patients
was 2.85 (95% CI 1.01–8.10, p=0.05, AIC 183.9). Incorporating
the baseline amount of acetylcholinesterase already aged and
plasma OP concentration into the analysis increased the HR to
3.94 (1.25–12.36, p=0.02) for patients receiving pralidoxime
compared to placebo, further decreasing the likelihood that
pralidoxime is beneficial.
We also examined the effect of pralidoxime for poisoning with
the two most common insecticides (chlorpyrifos and dimethoate,
Figure 6). Analysing patients poisoned by individual OPs reduces
the confounding caused by the marked variability that exists
between compounds of the same class. This analysis provided no
evidence that pralidoxime offers benefit for either compound.
Effectiveness of Pralidoxime in Reactivating
Acetylcholinesterase in Fatal Cases
We analysed whether death occurred after effective acetylcho-
linesterase reactivation, using an activity of .199 mU/mmol Hb
(20%–30% of normal) as an approximate level likely to be
compatible with normal synaptic function [32]. In patients
receiving pralidoxime, case fatality was lower in those with red
cell acetylcholinesterase activity .199 mU/mmol Hb at 1 h and
24 hr, compared to those with activity ,100 mU/mmol Hb (1 h:
.199, case fatality: 6/62 [9.7%] versus ,100, 15/30 [50.0%];
p,0.0001 Chi squared test; 24 h: .199, 5/51 [9.8%] versus
,100, 7/24 [29.2%]; p=0.03 Chi squared test). No such
difference was seen in patients receiving placebo at 1 h (.199,
1/5 [20.0%] versus ,100, 14/87 [16.1%]; p=0.82 Chi squared
test) and 24 h (.199, 0/4 [0%] versus ,100, 9/71 [12.7%];
p=0.45 Chi squared test). However, surprisingly, these data
showed that survival was still high (84%–87%) in patients receiving
placebo whose acetylcholinesterase activity remained very low at 1
and 24 h.
There was a significant difference in median post-treatment red
cell acetyl-cholinesterase activity between survivors and fatalities in
both arms (Table 3). The median acetylcholinesterase was lower in
survivors who received placebo than in those who died after
receiving pralidoxime.
Only two of the 30 deaths in the pralidoxime arm occurred after
the drug infusion was stopped in patients poisoned by fat-soluble
OPs, with subsequent reinhibition of red cell acetylcholinesterase.
This suggests that an inadequate duration of pralidoxime therapy
was not the cause of the majority of deaths.
Intubation
Eighty-six patients (86/235, 36.6%) required intubation. Forty
(40/235, 17.0%) were intubated at baseline (Table 1), while 50
were intubated postrandomisation (50/235, 21.3%; four for a
second time after postrandomisation extubation). Similar numbers
of patients were intubated postrandomisation in each arm: 26/121
(21.5%) receiving pralidoxime and 24/114 (21.1%) receiving
placebo (crude HR 1.23 [95% CI 0.70–2.14, p=0.47], adjusted
1.25 [0.68–2.27, p=0.47]). Incorporating baseline percentage
aged acetylcholinesterase and plasma insecticide concentration
Figure 1. CONSORT flow diagram of progress through the RCT. 162 patients were excluded due to receiving pralidoxime in the referring
hospital (151), being pregnant (7), or being less than 14 y old (4).
doi:10.1371/journal.pmed.1000104.g001
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into the statistical model increased the estimated HR to 1.80
(0.83–3.88, p=0.14).
Intubation occurred earlier in the pralidoxime arm (Figure 7).
Patients receiving pralidoxime were intubated for shorter periods:
median period 2.1 d (95% CI 0.8–4.8; n=45) versus 6.5 d (1.8–
10.1; n=37; p=0.02, Mann Whitney test). The picture was similar
when we analysed only postrandomisation intubations: median
period 3.5 d (0.8–4.7; n=26) versus 8.0 d (4.4–10.2; n=23;
p#0.001 Mann Whitney test). Some of this difference is likely to be
due to the greater number of deaths among intubated patients
treated with pralidoxime (25/48 [52.1%]) than those receiving
placebo (15/38 [39.5%]).
A post-hoc exploratory analysis suggested that patients who
received pralidoxime before intubation appeared to do worse than
patients who received it after intubation at baseline (Figure 8).
Adverse Events
Patients were assessed at the end of the loading dose and at 12 h
intervals for adverse effects [33]. Tachycardia, hypertension
(particularly diastolic), and vomiting were more common in patients
receiving pralidoxime (Table 4). Over the next 72 h, only
tachycardia and hypertension were more common in these patients.
Discussion
This trial showed no benefit from the administration of the
WHO’s recommended regimen of pralidoxime chloride to patients
with symptomatic OP insecticide poisoning. The primary
outcome—the (adjusted) HR showing higher mortality (1.69,
95% CI 0.88–3.26, p=0.12) in patients receiving pralidoxime—is
consistent with a broad range of effects: from a 12% reduction in
mortality to a greater than 3-fold increase in mortality. However,
the best estimate, i.e., the most likely effect from this trial, is a 69%
increase in mortality due to the treatment. The results from other
important outcomes in our trial, e.g. intubation, reinforce the
finding of a lack of benefit for the treatment.
No subgroup appeared to derive differential benefit. All
preplanned analyses failed to show that pralidoxime was
beneficial, even for compounds such as chlorpyrifos for which
there was expected to be the greatest chance of benefit and good
reactivation of red cell acetylcholinesterase. Adjustment for the
crucial baseline markers (OP ingested and extent of acetylcholin-
esterase ageing, measured for the first time in an OP trial) resulted
in even less favorable estimates of effect. Our study shows that the
WHO-recommended dose of pralidoxime is most likely to be
ineffective, and may be harmful.
Any serious adverse effects occurring from pralidoxime were not
clinically apparent. Case reports have suggested that pralidoxime
causes cardiac dysrhythmias or respiratory arrest [18,34] but these
effects may also be induced by the OP insecticides. We noted
marked diastolic hypertension in some patients receiving prali-
doxime but no increased incidence of respiratory or cardiac arrest
during or soon after the infusion started when the plasma
concentration was at its greatest. We observed no other substantial
Table 1. Baseline demographic and clinical characteristics.
Baseline Characteristic Subcategory Placebo (n=114) Pralidoxime (n=121)
Age, y, median (IQR) 29.5 (23 to 42) 31 (22 to 48)
Males, n (%) 92 (80.7) 96 (79.3)
Systolic BP, mmHg, mean (SD) 116 (19.8) 118 (22.7)
Diastolic BP, mmHg, mean (SD) 76 (13.4) 76 (17.2)
Pulse mean, bpm, mean (SD) 101 (22) 97 (21)
Time since ingestion, h, median (IQR) 4.4 (2.9 to 7.4); n=112 4.3 (2.9 to 7.8); n= 116
Time since ingestion using categorical variable
derived from times provided, n (%)
,4 h 53 (46.5) 51 (42.2)
4–12 h 41 (36.0) 45 (37.2)
.12 h 18 (15.8) 20 (16.5)
Unknown 2 (1.8) 5 (4.1)
Charcoal allocation for those in RCT, n (%) Multiple dose activated charcoal 8 (7.0) 13 (10.7)
Single dose activated charcoal 11 (9.7) 14 (11.6)
No activated charcoal 10 (8.8) 13 (10.7)
Not in RCT 85 (74.6) 81 (66.9)
Charcoal treatment, n (%) Multiple dose activated charcoal 8 (7.0) 13 (10.7)
Single dose activated charcoal 31 (27.2) 42 (34.7)
No activated charcoal 75 (65.8) 66 (54.6)
GCS score, median (IQR) 15 (12 to 15) 14 (10 to 15)
GCS score on admission, n (%) GCS 14 or 15 79 (69.3) 73 (60.3)
GCS,14 35 (30.7) 48 (39.7)
GCS 11–13 15 (13.2) 16 (13.2)
GCS 7–10 5 (4.4) 6 (5.0)
GCS 3–6 15 (13.2) 26 (21.5)
Intubated at baseline, n (%) 16 (14.0) 24 (19.8)
doi:10.1371/journal.pmed.1000104.t001
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adverse reactions that were attributed to pralidoxime at the time.
However, there was a trend toward worse outcomes in patients not
intubated before pralidoxime administration, suggesting that
intubation may be protective against adverse effects (e.g.,
respiratory, arrest).
Three medium-sized RCTs of pralidoxime have previously
been performed, two with pralidoxime chloride in Vellore [35,36]
and one with pralidoxime iodide in Baramati [29]. The studies
compared different doses of these pralidoxime salts (Table 5). The
Vellore studies compared a low-dose infusion with a single bolus
[35] or placebo [36]. They found the low-dose infusion to be
harmful, but there was a long delay to treatment in this trial and
few patients could have benefited [17]. In contrast, the Baramati
RCT found high doses (1 g of iodide salt, or 0.52 g of active
pralidoxime cation, per hour) for the first 48 h after a loading dose
to be beneficial, a difference previously related to more effective
pralidoxime concentration, less ill patients, and very early
treatment [37]. However, none of these studies took baseline
measures of acetylcholinesterase ageing and inhibition or identi-
fied the responsible OP to allow adjustment for baseline
differences. When we incorporated this information from our trial
into our analysis, we found a decreased likelihood that pralidoxime
is beneficial.
The Baramati RCT and our study used pralidoxime regimens
(Table 5) similar to that recommended by the WHO [24] yet
found very different results. It seems unlikely that this difference is
due to the different salts since the chloride should be at least as safe
as the iodide [37]. The median time to presentation in the two
Table 2. Baseline analytical laboratory characteristics.
Baseline Characteristics Subcategory Placebo (n=114) Pralidoxime (n=121)
OP insecticide class at randomisation, n (%) Dimethyl 47 (41.2) 46 (38.3)
Diethyl 49 (43.0) 54 (45.0)
Unknown 18 (15.8) 20 (16.7)
OP insecticide class after lab analysis, n (%) Number 112 121
Dimethyl 33 (29.5) 39 (32.2)
Diethyl 50 (44.6) 62 (51.2)
S-alkyl 2 (1.8) 0
Mixed 2 (1.8) 1 (0.8)
Unknown 21 (18.8) 16 (13.2)
No OP detected 4 (3.6) 3 (2.5)
BuChE activity on admission, mU/ml Number 103 106
Median (IQR) 110 (9 to 746) 86 (6 to 920)
Dimethyl, median (IQR) (n) 431 (20 to 1606) (n= 41) 733 (73 to 1876) (n= 39)
Diethyl, median (IQR) (n) 15 (0 to 144) (n= 46) 10 (0 to 99) (n= 49)
Other or unknown, median (IQR) (n) 122 (34 to 818) (n= 16) 121 (10 to 740) (n= 17)
Red cell AChE activity before treatment, mU/mmol Hb Number 92 102
Median (IQR) 28 (7 to 59) 44 (12 to 97)
Dimethyl, median (IQR) (n) 9 (2 to 32) (n=36) 17 (6 to 70) (n= 37)
Diethyl, median (IQR) (n) 47 (27 to 65) (n= 40) 60 (34 to 116) (n= 47)
Other or unknown, median (IQR) (n) 20 (6 to 115) (n= 16) 33 (4 to 68) (n= 17)
Aged red cell AChE before Rx, % Number 92 101
Median (IQR) 59 (34 to 96) 46 (29 to 89)
Dimethyl, median (IQR) (n) 97 (61 to 100) (n= 36) 89 (56 to 99) (n= 36)
Diethyl, median (IQR) (n) 34 (20 to 45) (n= 40) 35 (21 to 45) (n= 48)
Other or unknown, median (IQR) (n) 84 (47 to 92) (n= 16) 72 (34 to 100) (n= 16)
Data were collected on admission to hospital; recruitment occurred soon after.
Abbreviations: AChE, acetylcholinesterase; BuChE, butyrylcholinesterase.
doi:10.1371/journal.pmed.1000104.t002
Figure 2. Pharmacodynamics of oxime administration. Time
course of plasma pralidoxime concentration in patients allocated to
receive pralidoxime chloride 2 g loading dose over 20 min followed by
0.5 mg/h until 7 d or until atropine no longer required (blue line,
mean6SD; n#85). A predicted time course (green line) was calculated
for a 50 kg person using the kinetic data of Sidell and colleagues [42].
doi:10.1371/journal.pmed.1000104.g002
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studies was not markedly different: 2 h versus 4.4 h. One obvious
difference is the extent of supportive care. Baramati cases were
treated in an intensive care unit and 66% were intubated at
baseline, compared to 17.4% in our study, despite being less
severely ill. While some hospitals in rural Asia are able to offer
such a high standard of care, they are not the norm and most
patients present to hospitals similar to our study sites in Sri Lanka.
A second obvious difference is that high doses were used for only
48 h in the Baramati study but for up to 7 d in our study. The
difference in mortality in our study continued to increase over time
until at least 6 d postrandomisation (Figures 4 and 5).
This trial overlapped in part with another RCT of activated
charcoal [25]. However, as shown in Table 1, only 69/235
(29.4%) patients were recruited into the charcoal RCT and their
allocation was incorporated into the adjusted analysis. Further-
more, no effect of charcoal was noted in the RCT [25]. We
therefore do not think that the charcoal RCT confounded the
analysis of this RCT.
One limitation of this study was the lack of facilities for
monitoring of patients that might have allowed us to better
describe the cause of death in each patient, whether due to
complications of prehospital aspiration or respiratory arrest,
cholinergic syndrome, or cardiorespiratory arrest independent of
the above that would suggest direct adverse effects of the
pralidoxime. The study was therefore unable to explain why no
benefit was found from this dose of pralidoxime; however, such
information would not alter its conclusion.
A second limitation is that it was stopped early as a consequence
of a loss of equipoise in recruiting clinicians after we became aware
of the Baramati results. However, it has unique strengths, in
particular baseline stratification of patients by insecticide and red
cell acetylcholinesterase activity and ageing, as recommended by
others [38]. Furthermore, despite falling short of our recruitment
target, the clinical information we gathered, interpreted with the
surrogate biochemical data, suggests that this regimen of
pralidoxime is unlikely to be beneficial in our patient population.
Further interpretation of our results is not straightforward. We
are faced with the perplexing fact that pralidoxime effectively
reactivated diethyl-OP inhibited red cell acetylcholinesterase, but
did not improve outcome. Might OPs have other detrimental
effects that are not amenable to pralidoxime? The majority of the
insecticides ingested were generic products formulated with
xylene. It is possible that coformulants are responsible for a
significant component of toxicity [9].
The evidence for pralidoxime effectiveness beyond the contra-
dictory clinical trials is limited. Some evidence of effectiveness is
claimed from animal studies, although species differences in
acetylcholinesterase structure greatly affect OP binding and
reversal by oximes [39]. Moreover, these studies are largely
limited to single doses of pralidoxime given at the same time as a
smallish dose of OP insecticide, in the absence of any standard
titrated atropine treatment or supportive care [40]. They provide
no support that continuous pralidoxime infusions in addition to
usual care are useful. These studies do suggest we should move
toward using oximes that are more effective than pralidoxime or
have a better risk/benefit ratio [14,40].
Figure 3. Pharmacokinetics of oxime administration. Red cell
acetylcholinesterase activity (mean6SD) in patients poisoned by diethyl
(blue) and dimethyl (red) OP insecticides, with (solid) and without
(broken) pralidoxime chloride. Normal acetylcholinesterase activity is
600–700 mU/mmol Hb; an activity greater than 20%–30% of normal
allows normal NMJ function [32]. Acetylcholinesterase was effectively
reactivated after poisoning with diethyl insecticides but less so after
dimethyl insecticide poisoning.
doi:10.1371/journal.pmed.1000104.g003
Figure 4. Timing of deaths in the two study arms. Cumulative
percentage of patients who died. For the purposes of survival analysis,
the clock has been started at randomisation and stops either at death
or discharge (assumed to be 40 d if discharged alive sooner than 40 d).
doi:10.1371/journal.pmed.1000104.g004
Figure 5. Timing of deaths during the first 6 d. For the purposes
of survival analysis, the clock has been started at randomisation and
stops either at death or discharge (assumed to be 40 d if discharged
alive sooner than 40 d).
doi:10.1371/journal.pmed.1000104.g005
Pralidoxime for OP Insecticide Poisoning
PLoS Medicine | www.plosmedicine.org 7 June 2009 | Volume 6 | Issue 6 | e1000104
A second possible explanation is that pralidoxime is worthwhile
but the dose too high. Pralidoxime has a high in vitro effect on
human acetylcholinesterase at around 100 mmol/l [14], the target
concentration of our regimen and the basis for the regimen being
promoted by a WHO working group [24]. However, this may not
necessarily be the optimal human dose in terms of risk/benefit.
Further studies will be required to identify such a dose.
Another argument for a lower dose is that lesser degrees of
reactivation may still be clinically useful. We have shown that
red cell acetylcholinesterase activity in many survivors was less
than 25% of normal, indicating that complete reactivation
may be unnecessary. Aiming to achieve concentrations that
achieve nearly full reactivation may lead to significant adverse
effects.
The third possible explanation to consider is that there was a
benefit in some patients but too many patients derived no benefit;
that a more selective use might be useful. We chose, on pragmatic
grounds, to administer pralidoxime for a maximum of 7 d,
Figure 6. Forest plots of mortality for pralidoxime versus placebo for a priori defined study groups. The relatively few events precluded
plots of adjusted analyses.
doi:10.1371/journal.pmed.1000104.g006
Table 3. Median red cell acetylcholinesterase activity (mU/mmol Hb) in patients surviving or dying, by study arm, at 1 and 24 h
post-treatment.
Time Point Characteristic Placebo Arm Pralidoxime Arm
Baseline, median (IQR) 28 (7 to 59) 44 (12 to 97)
1 h n 101 103
Dead, median (IQR) 6 (0 to 15) 40 (21 to 206)
Alive, median (IQR) 31 (12 to 65) 286 (147 to 400)
Difference, median (95% CI; p-value) 23 (12 to 34; p= 0.0003) 182 (97 to 249; p=0.0001)
24 h n 86 86
Dead, median (IQR) 2 (0 to 8) 62 (0 to 287)
Alive, median (IQR) 45 (12 to 84) 302 (115 to 407)
Difference, median (95% CI; p-value) 40 (18 to 53; p= 0.002) 135 (27 to 251; p=0.01)
This table shows that patients who were allocated pralidoxime and survived had substantially higher red cell acetylcholinesterase activity after treatment than patients
receiving pralidoxime who died. Patients who survived without receiving pralidoxime had only a marginally higher acetylcholinesterase activity post-treatment than
people who died. This indicates that reactivated red cell acetylcholinesterase may not be essential for survival. Normal mean (6SD) red cell acetylcholinesterase in the
laboratory was 651618 mU/mmol Hb [27].
doi:10.1371/journal.pmed.1000104.t003
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presuming that this would be the maximum period of active
acetylcholinesterase inhibition in most patients. Oxime adminis-
tration was stopped when patients no longer required atropine,
indicating the presence of sufficient active acetylcholinesterase at
muscarinic synapses.
However, retrospective analysis of red cell acetylcholinester-
ase activity indicates that many patients received pralidoxime
at a time when no benefit was likely. This on its own does not
provide an explanation for the adverse trend but could have
been a contributing factor by increasing the time period for
adverse effects from pralidoxime to manifest. Discontinuation
or dose adjustment in response to rapid testing of the response
to pralidoxime might have improved the overall risk/benefit
ratio.
Conclusion
Clinicians are now faced with a difficult situation. Should
pralidoxime be given to patients with OP insecticide poisoning?
Patients with relatively low-dose occupational poisoning by diethyl
organophosphorus insecticides have been shown to clinically
improve after low-dose pralidoxime administration [41]. However,
for self-poisoned patients, we have no consistent clinical trial
evidence for the use of this regimen of pralidoxime in OP
insecticide poisoning. We believe that further trials are required to
assess the risk/benefit of oximes and to explore using lower or
shorter dosing regimens or different oximes. In all cases oximes
should be continued only where there is continuing evidence of
usefulness. Our trial provides evidence that routinely following the
WHO recommended high-dose pralidoxime regimen in all
patients does not improve survival in OP insecticide self-poisoned
patients.
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Table 5. Published RCTs of pralidoxime with more than 20 patients showing doses of the pralidoxime cation administered in each
arm.
Trial Salta
Pralidoxime Cation
per Gram of Salt Arm 1 Cation Dose Arm 2 Cation Dose
Vellore [35] Chlorideb 0.795 g 0.80 g loading dose over 1–5 min No loading dose, then infusion of 4.8 g over 1st 24 h, 2.4 g
over 2nd 24 h, 1.6 g over 3rd 24 h, and 0.8 g over 4th 24 h
Vellore [36] Chlorideb 0.795 g None No loading dose, then infusion of 9.5 g over 3 dc
Baramati [29] Iodide 0.520 g 1.04 g loading dose over 30 min,
then 0.52 infused over 1 hr every 4 h
1.04 g loading dose over 30 min, then 0.52 g/h constant
infusion for 48 h, then 0.52 g infused over 1 h every 4 h
This trial Chloride 0.795 g None 1.6 g loading dose over 20 min, then 0.4 g/h constant
infusion for up to 7 d
aThe different salts contain different quantities of pralidoxime [37,43].
bNot stated in papers. Personal communication, Dr. J. V. Peter.
cExact dosage regimen over the 3 d not stated in paper.
doi:10.1371/journal.pmed.1000104.t005
Table 4. Adverse effects reported in each arm after the pralidoxime chloride/placebo loading dose or during the first 3 d of the
constant infusion.
Adverse Effect Loading dose (t = 20 min) Constant infusion (t = 20 min to 72 h)
Placebo Pralidoxime p-Value Placebo Pralidoxime p-Value
Tachycardiaa, n (%) 30/110 (27.3) 61/115 (53.0) ,0.0001 54/111 (48.6) 85/114 (74.6) ,0.0001
Hypertensionb, n (%) 2/110 (1.8) 27/115 (23.5) ,0.0001 16/111 (14.4) 34/114 (29.8) 0.005
Headache, n (%) 5/110 (4.5) 7/115 (6.1) 0.61 33/111 (29.7) 36/114 (31.6) 0.76
Blurred vision, n (%) 3/110 (2.7) 8/115 (7.0) 0.14 26/111 (23.4) 40/114 (35.1) 0.06
Dizziness, n (%) 8/110 (7.3) 9/115 (7.8) 0.88 35/111 (31.5) 31/114 (27.2) 0.48
Nausea, n (%) 12/110 (10.9) 13/115 (11.3) 0.93 33/111 (29.7) 25/114 (21.9) 0.18
Vomiting, n (%) 8/110 (7.3) 21/115 (18.3) 0.01 24/111 (21.6) 26/114 (22.8) 0.83
Systolic BP, mmHg, mean (SD) 116 (15.3) 129 (27.6) ,0.0001 ND ND
Diastolic BP, mmHg, mean (SD) 74 (13.5) 80 (20.2) 0.015 ND ND
Pulse, bpm, mean (SD) 99 (20.1) 113 (22.8) ,0.0001 ND ND
aTachycardia, HR.100 bpm.
bHypertension, systolic BP.159 and/or diastolic.99 mmHg.
ND, not done.
doi:10.1371/journal.pmed.1000104.t004
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Editors’ Summary
Background. Each year, about 200,000 people worldwide
die from poisoning with organophosphorous insecticides,
toxic chemicals that are widely used in agriculture,
particularly in developing countries. Organophosphates
disrupt communication between the brain and the body in
both insects and people. The brain controls the body by
sending electrical impulses along nerve cells (neurons) to the
body’s muscle cells. At the end of the neurons, these
impulses are converted into chemical messages
(neurotransmitters), which cross the gap between neurons
and muscle cells (the neuromuscular junction) and bind to
proteins (receptors) on the muscle cells that pass on the
brain’s message. One important neurotransmitter is
acetylcholine. This is used at neuromuscular junctions, in
the part of the nervous system that controls breathing and
other automatic vital functions, and in parts of the central
nervous system. Normally, the enzyme acetylcholinesterase
quickly breaks down acetylcholine after it has delivered its
message, but organophosphates inhibit acetylcholinesterase
and, as a result, disrupt the transmission of nerve impulses at
nerve endings. Symptoms of organophosphate poisoning
include excessive sweating, diarrhea, muscle weakness, and
breathing problems. Most deaths from organophosphate
poisoning are caused by respiratory failure.
Why Was This Study Done? Treatment for
organophosphorous insecticide poisoning includes
resuscitation and assistance with breathing (intubation) if
necessary and the rapid administration of atropine. This
antidote binds to ‘‘muscarinic’’ acetylcholine receptors and
blocks the effects of acetylcholine at this type of receptor.
Atropine can only reverse some of the effects of
organophosphate poisoning, however, because it does not
block the activity of acetylcholine at its other receptors.
Consequently, the World Health Organization (WHO)
recommends that a second type of antidote called an
oxime acetylcholinesterase reactivator be given after
atropine. But, although the beneficial effects of atropine
are clear, controversy surrounds the role of oximes in
treating organophosphate poisoning. There is even some
evidence that the oxime pralidoxime can be harmful. In this
study, the researchers try to resolve this controversy by
studying the effects of pralidoxime treatment on patients
poisoned by organophosphorous insecticides in Sri Lanka in
a randomized controlled trial (a study in which groups of
patients are randomly chosen to receive different
treatments).
What Did the Researchers Do and Find? The researchers
enrolled 235 adults who had been admitted to two Sri
Lankan district hospitals with organophosphorous
insecticide self-poisoning (in Sri Lanka, more than 70% of
fatal suicide attempts are the result of pesticide poisoning).
The patients, all of whom had been given atropine, were
randomized to receive either the WHO recommended
regimen of pralidoxime or saline. The researchers
determined how much and which pesticide each patient
had been exposed to, measured the levels of pralidoxime
and acetylcholinesterase activity in the patients’ blood, and
monitored the patients’ progress during their hospital stay.
Overall, 48 patients died—30 of the 121 patients who
received pralidoxime and 18 of the 114 control patients.
After adjusting for the baseline characteristics of the two
treatment groups and for intubation at baseline, pralidoxime
treatment increased the patients’ risk of dying by two-thirds,
although this increased risk of death was not statistically
significant. In other words, this result does not prove that
pralidoxime treatment was bad for the patients in this trial.
However, in further analyses that adjusted for the ingestion
of different insecticides, the baseline levels of insecticides in
patients’ blood, and other prespecified variables, pralidoxime
treatment always increased the patients’ risk of death.
What Do These Findings Mean? These findings provide
no evidence that the WHO recommended regimen of
pralidoxime improves survival after organophosphorous
pesticide poisoning even though other results from the
trial show that the treatment reactivated
acetylcholinesterase. Indeed, although limited by the small
number of patients enrolled into this study (the trial
recruited fewer patients than expected because results
from another trial had a deleterious effect on recruitment),
these findings actually suggest that pralidoxime treatment
may be harmful at least in self-poisoned patients. This
suspicion now needs be confirmed in trials that more fully
assess the risks/benefits of oximes and that explore the
effects of different dosing regimens and/or different oximes.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000104.
N The US Environmental Protection Agency provides infor-
mation about all aspects of insecticides (in English and
Spanish)
N Toxtown, an interactive site from the US National Library of
Medicine provides information on exposure to pesticides
and other environmental health concerns (in English and
Spanish)
N The US National Pesticide Information Center provides
objective, science-based information about pesticides (in
English and Spanish)
N MedlinePlus also provides links to information on pesti-
cides (in English and Spanish)
N For more on Poisoning Prevention and Management see
WHO’s International Programme on Chemical Safety (IPCS)
N WikiTox, a clinical toxicology teaching resource project, has
detailed information on organophosphates
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